Robert T O'Donnell MD
Professor, Internal Medicine, UC, Davis School of Medicine
Join to View Full Profile
2279 45th StSacramento, CA 95817
Phone+1 916-734-5959
Fax+1 916-703-5265
Dr. O'Donnell is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of California Davis HealthFellowship, Hematology and Medical Oncology, 1990 - 1993- University of California Davis HealthResidency, Internal Medicine, 1987 - 1990
Loyola University Chicago Stritch School of MedicineClass of 1987
Certifications & Licensure
CA State Medical License 1988 - 2022
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma Start of enrollment: 2008 Jun 01
Publications & Presentations
PubMed
- 5 citationsNovel mTORC1 Inhibitors Kill Glioblastoma Stem Cells.Jose Sandoval, Alexey Tomilov, Sandipan Datta, Sonia A. Allen, Robert T. O'Donnell
Pharmaceuticals. 2020-11-24 - 10 citationsA phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemiaBenjamin Tomlinson, Joseph Tuscano, Mehrdad Abedi, Jeanna L Welborn, Mili Arora
American Journal of Hematology. 2019-11-01 - 12 citationsA phase I trial of escalating doses of cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular carcinoma.Anthony B. El-Khoueiry, Robert T. O'Donnell, Thomas J. Semrad, Philip C. Mack, Suzette Blanchard
Cancer Chemotherapy and Pharmacology. 2018-03-08
Grant Support
- Immunoliposomal Therapy Of Non-Hodgkin'S LymphomaVeterans Affairs2012
- Phasei/Ii Clinical Trial Of Hhb22.7 Anti-Cd22 Monoclonal Antibody For LymphomaNational Cancer Institute2006–2007
- Combined Modality Radioimmunotherapy For Nonhodgkins LymphomaNational Cancer Institute1999–2002
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
